An open-label study of sodium oxybate in spasmodic dysphonia

Rumbach, Anna F., Blitzer, Andrew, Frucht, Steven J. and Simonyan, Kristina (2017) An open-label study of sodium oxybate in spasmodic dysphonia. Laryngoscope, 127 6: 1402-1407. doi:10.1002/lary.26381


Author Rumbach, Anna F.
Blitzer, Andrew
Frucht, Steven J.
Simonyan, Kristina
Title An open-label study of sodium oxybate in spasmodic dysphonia
Journal name Laryngoscope   Check publisher's open access policy
ISSN 0023-852X
1531-4995
Publication date 2017-06-01
Year available 2017
Sub-type Article (original research)
DOI 10.1002/lary.26381
Open Access Status Not yet assessed
Volume 127
Issue 6
Start page 1402
End page 1407
Total pages 6
Place of publication Hoboken, NJ United States
Publisher John Wiley & Sons
Language eng
Abstract Objectives/Hypothesis: Spasmodic dysphonia (SD) is a task-specific laryngeal dystonia that affects speech production. Co-occurring voice tremor (VT) often complicates the diagnosis and clinical management of SD. Treatment of SD and VT is largely limited to botulinum toxin injections into laryngeal musculature; other pharmacological options are not sufficiently developed.
Formatted abstract
Objectives/Hypothesis: Spasmodic dysphonia (SD) is a task-specific laryngeal dystonia that affects speech production.Co-occurring voice tremor (VT) often complicates the diagnosis and clinical management of SD. Treatment of SD and VT islargely limited to botulinum toxin injections into laryngeal musculature; other pharmacological options are not sufficientlydeveloped.
Study Design: Open-label study.Methods: We conducted an open-label study in 23 SD and 22 SD/VT patients to examine the effects of sodium oxybate(Xyrem), an oral agent with therapeutic effects similar to those of alcohol in these patients. Blinded randomized analysis ofvoice and speech samples assessed symptom improvement before and after drug administration.
Results: Sodium oxybate significantly improved voice symptoms (P 5 .001) primarily by reducing the number ofSD-characteristic voice breaks and severity of VT. Sodium oxybate further showed a trend for improving VT symptoms (P 5.03) in a subset of patients who received successful botulinum toxin injections for the management of their SD symptoms.The drug’s effects were observed approximately 30 to 40 minutes after its intake and lasted about 3.5 to 4 hours.
Conclusions: Our study demonstrated that sodium oxybate reduced voice symptoms in 82.2% of alcohol-responsiveSD patients both with and without co-occurring VT. Our findings suggest that the therapeutic mechanism of sodium oxybatein SD and SD/VT may be linked to that of alcohol, and as such, sodium oxybate might be beneficial for alcohol-responsive SDand SD/VT patients.
Keyword Laryngeal dystonia
Xyrem
alcohol
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID R01DC012545
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Health and Rehabilitation Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 12 Jun 2017, 11:29:00 EST by Ms Anna Rumbach on behalf of School of Health & Rehabilitation Sciences